Barthélemy, Nicolas R.
Salvadó, Gemma http://orcid.org/0000-0002-5210-9230
Schindler, Suzanne E. http://orcid.org/0000-0002-1680-1465
He, Yingxin http://orcid.org/0000-0003-2543-4553
Janelidze, Shorena http://orcid.org/0000-0003-2869-8378
Collij, Lyduine E. http://orcid.org/0000-0001-6263-1762
Saef, Benjamin
Henson, Rachel L.
Chen, Charles D.
Gordon, Brian A. http://orcid.org/0000-0003-2109-2955
Li, Yan
La Joie, Renaud http://orcid.org/0000-0003-2581-8100
Benzinger, Tammie L. S. http://orcid.org/0000-0002-8114-0552
Morris, John C.
Mattsson-Carlgren, Niklas
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Ossenkoppele, Rik http://orcid.org/0000-0003-1584-7477
Rabinovici, Gil D. http://orcid.org/0000-0002-3626-4265
Stomrud, Erik
Bateman, Randall J. http://orcid.org/0000-0002-7729-1702
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Article History
Received: 24 October 2023
Accepted: 12 February 2024
First Online: 21 February 2024
Competing interests
: N.R.B. and R.J.B. are co-inventors on US patent applications: ‘Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer’s disease and other tauopathies’ and ‘CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies’. N.R.B. and R.J.B. are co-inventors on a non-provisional patent application: ‘Methods of diagnosing and treating based on site-specific tau phosphorylation’. S.E.S. served on a scientific advisory board for Eisai. T.L.S.B. has investigator-initiated research funding from the National Institutes of Health, the Alzheimer’s Association, the Barnes-Jewish Hospital Foundation and Siemens. She participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Janssen and Roche. She also serves as a consultant to Biogen, Eli Lilly, Eisai and Siemens. Neither J.C.M. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. O.H. has acquired research support (for the institution) from ADx, Avid Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche and Siemens. R.J.B. co-founded C2N Diagnostics. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics, blood plasma assay and methods of diagnosing Alzheimer’s disease with phosphorylation changes) that is licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. R.J.B. has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. O.H. has acquired research support (for the institution) from ADx, Avid Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Myers Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.P. has acquired research support (for the institution) from ki:elements / Alzheimerʼs Drug Discovery Foundation. In the past 2 years, he has received consultancy/speaker fees from BioArtic, Biogen, Eli Lilly and Roche. L.E.C. has received research support from GE Healthcare (paid to institution). G.D.R. has received research support from Avid Radiopharmaceuiticals, GE Healthcare, Life Molecular Imaging and Genentech and consulting fees from Alector, Eli Lilly, Johnson & Johnson and Merck and serves as Associate Editor for J<i>AMA Neurology</i>. The other authors have no competing interests.